Back to search

Article

Safety and Immunogenicity of SARS-Cov-2 Vaccine MVC-COV1901– Do Elderly Need a Higher Dose?

2022-08-01

Abstract excerpt

Older adults are subject to higher COVID-19 infection and mortality rates. Even though vaccination programs prioritize the elderly, they are under-represented in clinical trials. Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine has been demonstrated in phase 2 clinical trial for the general population, and negative correlations have been observed between immune responses and age. To further asse...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ecc6c9b6-0e01-5a51-be8a-cbd0a99d7808
DOI
10.21203/rs.3.rs-1850379/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and Immunogenicity of SARS-Cov-2 Vaccine MVC-COV1901– Do Elderly Need a Higher Dose?DOI 10.21203/rs.3.rs-1850379/v1
A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in AdultsSemantic proximity
Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 TrialSemantic proximity
STUDY PROTOCOL A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): A trial conducted within the VACCELERATE networkSemantic proximity
An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled studySemantic proximity
Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenSemantic proximity
Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal studySemantic proximity
A Phase I, Prospective, Randomized, Open-Labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in AdultsSemantic proximity
Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Elderly People Over 85 Years of Age in GreeceSemantic proximity
The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901: An extension to an open-label, dose-escalation, and non-randomized phase 1 studySemantic proximity
Second Boost of Omicron SARS-CoV-2 S1 Subunit Vaccine Induced Broad Humoral Immune Responses in Elderly MiceSemantic proximity
Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adultsSemantic proximity
Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized studySemantic proximity
Select a neighboring publication to make it the new centre.